Pembrolizumab (Keytruda), approved in 2014, targets PD-1 and is used for several sorts of cancer, including non-small cell lung cancer, melanoma, and urothelial carcinoma, and is used in combination with different chemotherapy regimens. The gene discussed is PDCD1; the disease is cancer.